AURA FAT PROJECTS ACQUISITION CORP

Metformin Trial Targeting Aging Awaits Funding Despite Billionaire Interest in Longevity

3 years ago

• The TAME trial aims to demonstrate that metformin, a drug approved for diabetes, can delay multiple age-related diseases like cardiovascular disease, cancer, and cognitive decline. • Nir Barzilai's TAME trial received FDA agreement in 2015 but has struggled to secure the $30-50 million needed, as philanthropists favor 'moonshot' projects over repurposing generic drugs. • Experts believe the TAME trial could establish a framework for biotech companies, proving that targeting aging is a viable strategy for preventing multiple diseases simultaneously. • Barzilai is now seeking funding from crypto-millionaires and Hevolution, hoping to launch the trial and establish aging as an indication for drug approval.